Kerroin aiemmin miten Ruotsissa on herännyt käsitys, että Ruotsissa ja monessa muussa maassa tehdään sukupuolen korjauksen nimissä ihmiskokeita nuorilla ja nuorilla aikuisilla:
”Satoja lapsia altistetaan Ruotsissa vuosittain hormonaaliselle ’hoidolle’ ja sen jälkeiselle sukuelinten silpomiselle, ilman että sille olisi olemassa minkäänlaista tieteellistä tai kokemukseen perustuvaa näyttöä".
According to Karolinska’s newest policy, which went into effect in May 2021, going forward, hormonal (puberty blocking and cross-sex hormone) interventions for gender-dysphoric minors may only be provided in a research setting approved by Sweden’s ethics review board. The policy states that careful assessment of the patient’s maturity level must be conducted to determine if the patient is capable of providing meaningful informed consent. There is also a requirement that patients and guardians are provided with adequate disclosures of the risks and uncertainties of this treatment pathway. It is not clear whether minors under the age of 16 would be eligible for such trials.
The Karolinska Hospital’s new policies echo a growing international concern over the proliferation of medical interventions that have a low certainty of benefits, while carrying a significant potential for medical harm. The latest policy issued by the Karolinska cites the UK NICE evidence review, which found the risk / benefit ratio of hormonal interventions for minors highly uncertain; the 2020 UK judicial review, which highlighted the overarching ethical problems with the practice of medical "affirmation" of minors; as well as Sweden's own Health and Technology Assessment (SBU) evidence review conducted in 2019, which found a lack of evidence for medical treatments, and a lack of explanation for the sharp increase in the numbers of adolescents presenting with gender dysphoria in recent years.
Ei kommentteja:
Lähetä kommentti